Naltrexone/Buproprion

Clare Lee, M.D., MHS, Brian Pinto, Pharm.D.
Naltrexone/Buproprion is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Naltrexone/bupropion was approved as an adjunct to diet and exercise in adults with BMI ≥30 kg/m2 or ≥27 kg/m2 with one or more weight-related comorbidities to achieve weight loss.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: August 22, 2017

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Naltrexone/Buproprion ID - 547197 A1 - Lee,Clare,M.D., MHS AU - Pinto,Brian,Pharm.D. Y1 - 2017/08/22/ PB - Johns Hopkins Diabetes Guide UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547197/all/Naltrexone_Buproprion ER -